-
Gene therapy of rare diseases as a milestone in medicine [Elektronski vir] : overview of the field and report on initial experiences in SloveniaGrošelj, Urh ...Gene therapy has transitioned from a long-awaited promise to a clinical reality, offering transformative treatments for rare congenital diseases and certain cancers, which have a significant impact ... on patients’ lives. Current approaches focus on gene replacement therapy, either in vivo or ex vivo, mostly utilizing viral vectors to deliver therapeutic genes into target cells. However, refining these techniques is essential to overcome challenges and complications associated with gene therapy to ensure long-term safety and efficacy. Slovenia has witnessed significant advancements in this field since 2018, marked by successful gene therapy trials and treatments for various rare diseases. Significant strides have been made in the field of gene therapy in Slovenia, treating patients with spinal muscular atrophy and rare metabolic disorders, including the pioneering work on CTNNB1 syndrome. Additionally, immune gene therapy, exemplified by IL-12 adjuvant therapy for cancer, has been a focus of research in Slovenia. Through patient-centred initiatives and international collaborations, researchers in Slovenia are advancing preclinical research and clinical trials, paving the way for accessible gene therapies. Establishing clinical infrastructure and genomic diagnostics for rare diseases is crucial for gene therapy implementation. Efforts in this regard in Slovenia, including the establishment of a Centre for Rare Diseases, Centre for the Technologies of Gene and Cell Therapy, and rapid genomic diagnostics, demonstrate a commitment to comprehensive patient care. Despite the promises of gene therapy, challenges remain, including cost, distribution, efficacy, and long-term safety. Collaborative efforts are essential to address these challenges and ensure equitable access to innovative therapies for patients with rare diseases.Vir: Orphanet journal of rare diseases [Elektronski vir]. - ISSN 1750-1172 (Vol. 20, article no. 279, 2025, str. 1-10)Vrsta gradiva - e-članek ; neleposlovje za odrasleLeto - 2025Jezik - angleškiCOBISS.SI-ID - 238642179
Avtor
Grošelj, Urh |
Kavčič, Marko, medicina |
Drole Torkar, Ana, 1983- |
Kafol, Jan |
Lainšček, Duško |
Jerala, Roman |
Sever, Matjaž, 1976- |
Zver, Samo, 1966- |
Serša, Gregor |
Čemažar, Maja |
Strojan, Primož |
Grošelj, Aleš |
Žerjav-Tanšek, Mojca |
Miroševič, Špela |
Ivančan, Simona, dr. med. |
Prelog, Tomaž, medicina |
Gosar, David |
Oražem, Jasna |
Mlinarič, Matej, medicina |
Bertok, Sara, 1976- |
Kovač, Jernej, medicina |
Kodrič, Jana |
Battelino, Saba |
Pokorn, Marko |
Ihan, Alojz, 1961-2026 |
Jazbec, Janez, dr. med. |
Battelino, Tadej |
Osredkar, Damjan
Teme
gene therapy |
rare genetic diseases |
Slovenia |
CAR-T cells |
cancer |
immune gene therapy
| Avtor | Grošelj, Urh ... |
| Naslov | Gene therapy of rare diseases as a milestone in medicine [Elektronski vir] : overview of the field and report on initial experiences in Slovenia |
| Datum objave | 2025-06-05 |
| COBISS.SI-ID | 238642179 |
| Verzija objave v repozitoriju | Založnikova različica |
| Licenca objave v repozitoriju | Creative Commons Priznanje avtorstva 4.0 Mednarodna |
| Embargo | Takojšnja javna objava |
Projekti in financerji, navedeni v objavi
| Naziv | Akronim | Številka projekta | Financer |
|---|---|---|---|
| Etiologija, zgodnje odkrivanje in zdravljenje bolezni pri otrocih in mladostnikih | P3-0343-2022 |
Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije Slovenian Research and Innovation Agency |
|
| Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev | P3-0003-2022 |
Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije |
|
| Inovativna imunoterapija raka preko CAR T celic (CARRS) | J7-4640-2022 |
Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije |
|
| POVEZAVA MED GENOTIPOM IN FENOTIPOM PRI SINDROMU CTNNB1 IN NOVI PRISTOPI K ZDRAVLJENJU TEGA SINDROMA | J7-4537-2022 |
Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije |
|
| Himerna avtologna vakcina proti PCSK9 | J3-4526-2022 |
Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije |
|
| Uporaba izboljšanega sistema CRISPR/Cas za nevirusno produkcijo celic CAR-T | J4-4563-2022 |
Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije |
|
| Genska imunska terapija čvrstih tumorjev na osnovi mRNA z zapisom za interlevkin-12: So-rIL | L3-50111-2023 |
Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije |
|
| Centre of Excellence for the Technologies of Gene and Cell Therapy | CTGCT | 101059842 |
European Commission |
Datoteke, ki spadajo k objavi
| Povezava |
|---|
|
|
|
|
Stroški objave
| Vrsta stroška | Skupni stroški | Plačila |
|---|---|---|
| APC – strošek objave članka | 2490.00 € |
2490.00 € : Univerzitetni klinični center Ljubljana |
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
| Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
|---|---|---|---|---|---|---|---|---|
| JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP | |
Faktor vpliva
Baze podatkov, v katerih je revija indeksirana
| Ime baze podatkov | Področje | Leto |
|---|
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
| Mesto prevzema | Status gradiva | Rezervacija |
|---|
Prosimo, počakajte trenutek.
